COMP <GO>
SRRK vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Scholar Rock Holding Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SRRK 3
— JNJ 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SRRK
LAST: $43.90 (-0.63%) • MKT CAP: $5.38B
balance-sheet
13.67
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRRK | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 67.90% | -23.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.59% | 2.97% | -8.56 | JNJ | /fcf-yield <GO> |
| Operating Margin | 16.50% | 34.70% | -18.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 28.50% | -16.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 6.00% | +1.70 | SRRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 13.67 | 5.59 | +8.08 | SRRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.20% | -0.20 | SRRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 60.4 | -11.11 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.08 | -0.06 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 23.0x | +9.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $662.49B | -$657.11B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRRK REV | JNJ REV | SRRK GROSS % | JNJ GROSS % | SRRK FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$300.6M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$201.0M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$145.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
JNJ // BETA 1.08